The gating strategy is shown in Figure 2 , panel a.
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Supplementary Figure S3 . Frequency of ex vivo CD8 + specific responses to 15mer peptides in AERAS-402. To map epitopes recognized by CD8 + T cells to AERAS-402, a participant's ex vivo response was determined by IFN-γ ELISPOT in response to all 15mers for the three antigens contained in AERAS-402 (Ag85A, Ag85B, TB10.4) and then with the peptide pool. CD8 + T cells were positively selected from PBMC using magnetic beads (Stemcell Technologies) such that >97% of the cell population were CD8 + T cells. These CD8 + T cells were used as a source of responder T cells and tested in duplicate at a cell concentration of 250,000 cells per well. Autologous DC (20,000 cells/well) were used as APC and peptide pools (5 ug/ml, final concentration of each peptide) were added to the assay. Where sufficient PBMC was not available to make DC, CD4 depleted cells were used (CD8/others*). The antigen is followed by the participant identification in parentheses. Stable CD8 + T cell clones that were derived are illustrated (+) and also summarized in Table 4 . For participant 01805, clone A4-2(4) Ag85B 65-79 and clone A6-2(0) Ag85B 249-263 , the Ag85a illustration (±) denotes that we did not have sufficient PBMC to perform ex-vivo deconvolution of the Ag85B peptide pool. Adverse events (incl con meds) x x x x x x x Serious adverse events (incl con meds) a. These screening evaluations were done no earlier than 7 days prior to BCG administration on Study Day -84 and 3 days prior to study vaccine administration on Study Day 0 and Study Day 28. b. Serum chemistries = ALT, AST, total bilirubin, ALP and creatinine. c. Vital signs (blood pressure, heart rate, oral temperature) obtained pre-vaccination, and 30±5 and 60±5 minutes post-vaccination. d. Study Day 98 leukapheresis was performed any time after the Study Day 56 visit but no later than the Study Day 98 visit. e. Follow-up for serious adverse events is continued by 6-monthly telephone contact as part of the Registry Protocol. f.
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For females of child-bearing potential only. Serum -hCG was done no earlier than 7 days prior to Study Day -84. Urine -hCG was done on Study Day -84 prior to BCG administration and on Study Day 0 and Study Day 28 prior to study vaccine administration. g. Phlebotomy volumes were based on the following estimates: Serum -hCG: 1 mL, QuantiFERON: 3 mL, Hepatitis B/C: 4 mL, HIV-1: 2 mL, Chemistry: 2 mL, CBC: 5 mL, AERAS-402 neutralization: 7 mL, HLA: 5 mL, ICS: 24 mL, ELISPOT: 16 mL. h. Update medical history and physical examination from Study Days -84 through Study Day 0. Note: The amount of blood required for this study is within WHO guidelines for blood donation.
